Novartis pays big premium to get hands on AveXis in $8.7 billion deal

ZURICH (Reuters) – Novartis plans to buy AveXis for $218 per share in a $8.7 billion cash deal, adding a therapy hopeful for spinal muscular atrophy (SMA) to the Swiss drugmaker’s pipeline that is expected to reap billions in annual sales.

Source: Reuters

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>